Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gut microbiota carbohydrate-active enzymes (CAZymes) are a vast array of enzymes encoded by the collective genomes of the intestinal microbiota that facilitate the breakdown, synthesis, and modification of complex carbohydrates. While the human genome contains fewer than 100 enzymes for carbohydrate digestion, the gut microbiome provides thousands of CAZymes, enabling the host to extract energy from otherwise indigestible dietary fibers and plant polysaccharides [1][2]. These enzymes, which include glycoside hydrolases, glycosyltransferases, and polysaccharide lyases, convert complex glycans into short-chain fatty acids (SCFAs) like butyrate and acetate, which play critical roles in host immunity and metabolic health [3]. The specific profile of CAZymes within an individual's gut determines their capacity to ferment different types of fiber, influencing the production of beneficial metabolites [2]. Alterations in the abundance and diversity of CAZymes are linked to metabolic disorders like obesity and type 2 diabetes, as well as inflammatory conditions such as Crohn's disease [2][4]. Therapeutically, CAZymes are targeted by alpha-glucosidase inhibitors like acarbose to manage blood glucose levels by slowing the breakdown of starches [1]. Additionally, CAZymes are the primary targets of prebiotic interventions, where specific glycans are introduced to selectively enrich microbial taxa possessing the corresponding enzymatic machinery to restore gut homeostasis [3][4]. Sources: [1] Lombard V, et al. (2014). The Carbohydrate-active enzymes database (CAZy) in 2013. Nucleic Acids Res. [2] El Kaoutari A, et al. (2013). The abundance and variety of carbohydrate-active enzymes in the human gut microbiota. Nat Rev Microbiol. [3] Wardman JF, et al. (2022). Carbohydrate-active enzymes (CAZymes) in the gut microbiome. Nat Rev Microbiol. [4] Louis P, et al. (2014). The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol.
Competitive inhibition of microbial and host glycoside hydrolases to delay glucose absorption; selective substrate-driven enrichment of specific microbial taxa to modulate metabolite production.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiota carbohydrate-active enzyme (CAZyme).